- Conditions
- Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis, Non-infectious Pan Uveitis
- Interventions
- Brepocitinib
- Drug
- Lead sponsor
- Priovant Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Palo Alto, California • Pasadena, California + 12 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–35
of 11
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Axial Spondylarthritis (axSpA)
- Interventions
- Upadacitinib 15 MG [Rinvoq]
- Drug
- Lead sponsor
- CARE ARTHRITIS LTD.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Cytomegalovirus Anterior Uveitis
- Interventions
- Valganciclovir Hydrochloride, Ganciclovir Sodium, Placebo Oral Tablet, Topical placebo
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Uveitis, Anterior
- Interventions
- EGP-437 1.6 mA-min at 0.4 with EyeGate® II System, EGP-437 4.8 mA-min at 1.2 mA with EyeGate® II System, EGP-437 10.0 mA-min at 2.5 mA with EyeGate® II System, EGP-437 14.0 mA-min at 3.5 mA with EyeGate® II System
- Drug
- Lead sponsor
- Eyegate Pharmaceuticals, Inc.
- Industry
- Eligibility
- 12 Years to 85 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 13
- States / cities
- Miami, Florida • Atlanta, Georgia • Boston, Massachusetts + 10 more
- Conditions
- Anterior Uveitis, Posterior Uveitis, Panuveitis, Uveitis
- Interventions
- Not listed
- Lead sponsor
- The New York Eye & Ear Infirmary
- Other
- Eligibility
- 18 Years to 95 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Anterior Uveitis
- Interventions
- 40 mg/mL Dexamethasone phosphate ophthalmic solution, Prednisolone Acetate (1%) Eyedrops, 100 mM sodium citrate buffer solution, Placebo Eyedrops
- Drug
- Lead sponsor
- Eyegate Pharmaceuticals, Inc.
- Industry
- Eligibility
- 12 Years to 85 Years
- Enrollment
- 193 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 34 more
- Conditions
- Uveitis
- Interventions
- Izokibep, Prednisone/Prednisolone
- Drug
- Lead sponsor
- ACELYRIN Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Palo Alto, California • Hagerstown, Maryland + 1 more
- Conditions
- Anterior Uveitis (AU), Birdshot Chorioretinitis, Behcet Disease, Herpes Simplex Virus, Juvenile Idiopathic Arthritis (JIA), Spondyloarthritis (SA), Sarcoidosis, Posterior Vitreous Detachment
- Interventions
- Not listed
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 5 Years to 85 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate, Panuveitis
- Interventions
- Ixekizumab Prefilled Syringe
- Drug
- Lead sponsor
- Massachusetts Eye Research and Surgery Institution
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Waltham, Massachusetts
- Conditions
- Cytomegalovirus (CMV), Anterior Uveitis, Infectious Uveitis, CMV Infection
- Interventions
- Valganciclovir, Ganciclovir (GCV), Placebo
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 117 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2032
- U.S. locations
- 2
- States / cities
- Los Angeles, California • San Francisco, California
- Conditions
- Non-infectious Anterior Uveitis
- Interventions
- NS2, Prednisolone acetate ophthalmic suspension (1%)
- Drug
- Lead sponsor
- Aldeyra Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 15
- States / cities
- Lancaster, California • Golden, Colorado • Hamden, Connecticut + 12 more